DoseMe, a global leader in model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, has announced the acquisition of Firstline, a leading clinical decision support platform used by clinicians worldwide. The transaction brings together two innovative healthcare technology platforms to deliver an end-to-end solution for clinicians, helping them move seamlessly from evidence-based treatment selection to individualized precision dosing.
Headquartered in Jupiter, Florida, and Vancouver, British Columbia, the combined organization aims to strengthen the global fight against infectious disease by improving antimicrobial stewardship (AMS), advancing patient outcomes, and reducing healthcare costs. Firstline’s platform provides clinicians with rapid access to local treatment protocols for contagious diseases, susceptibility data, and stewardship resources. Meanwhile, DoseMe’s technology enables clinicians to calculate personalized dosing in seconds, based on patient characteristics and pharmacokinetic models.
The merger responds to the growing global challenge of antibiotic resistance, which costs the U.S. healthcare system an estimated $21 billion to $34 billion annually and results in more than 8 million excess hospital days. With this acquisition, DoseMe and Firstline seek to help health systems convert stewardship policy into real-time, actionable intelligence at the point of care.
The integration creates a single connected platform that bridges the gap between AMS policy and practice, allowing hospitals, governments, and healthcare organizations worldwide to accelerate precision care. Fairlong Capital, which backs DoseMe, said the acquisition will enhance the company’s ability to deliver personalized medicine solutions that drive both clinical and economic value.
KEY QUOTES:
“Firstline is the perfect complement to DoseMe with proven value that provides impact on patient outcomes, hospital ecology, and combating antimicrobial resistance. Together, we support AMS initiatives and speed up optimized patient care decisions by helping clinicians access local stewardship protocols and translate them directly into personalized precision dosing.”
Paul Edwards, CEO of DoseMe
“We’re immensely proud to have built Firstline into an organization delivering clinical guidance globally to hospitals, governments and the World Health Organization. We’re excited to see Firstline continue to flourish as part of the larger DoseMe organization.”
Dr. Michael Long, Co-founder and Chief Clinical Officer of Firstline
“The combination of DoseMe and Firstline advances the mission to address the full patient care continuum of personalized medicine. We look forward to the consolidated business’ continued growth, but most importantly to the profound impact this combination will have on the customer’s ability to improve patient care.”
David Neiman, Managing Partner at Fairlong Capital
